the Effects of Different Therapy Regimens on Menopausal Sleep Disorders

NCT ID: NCT06117969

Last Updated: 2024-01-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-30

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sleeping disorders are one of the most common menopausal symptoms, which seriously affect health and life quality of perimenopausal women. Menopausal hormone therapy is an effective treatment for menopausal symptoms, meanwhile, traditional Chinese medicine is also effective to some extent. This prospective randomized controlled study plan to compare the effects of different therapy regimens, including Tibolone and Xiangshao granules, on menopausal sleep disorders.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Menopause Sleep Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tibolone

take Tibolone 1.25mg/day orally for 8 weeks

Group Type EXPERIMENTAL

Tibolone

Intervention Type DRUG

1.25mg po qd

Xiangshao granules

take Xiangshao granules orally 3 times a day, 4g each time

Group Type EXPERIMENTAL

Xiangshao granules

Intervention Type DRUG

4g po tid

Tibolone plus Xiangshao granules

take Tibolone 1.25mg/day and Xiangshao granules 3 times a day, 4g each time orally for 8 weeks

Group Type EXPERIMENTAL

Tibolone plus Xiangshao granules

Intervention Type DRUG

Tibolone 1.25mg po qd plus Xiangshao granules 4g po tid

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tibolone

1.25mg po qd

Intervention Type DRUG

Xiangshao granules

4g po tid

Intervention Type DRUG

Tibolone plus Xiangshao granules

Tibolone 1.25mg po qd plus Xiangshao granules 4g po tid

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women aged 40-60
* natural menopause for 1-10 years
* PSQI score \>=11 points
* improved K-score\>=14 points
* able to independently sign informed consent forms

Exclusion Criteria

* Vaginal bleeding of unknown cause
* Known or suspected breast cancer and other sex hormone dependent tumors
* Active venous or arterial thromboembolic disease within past 6 months
* Have used sex hormone or traditional Chinese medicine/botanical drugs that affect menopausal symptoms within the past month
* Have used anti anxiety, depression drugs or sedative hypnotics within the past month
* Patients with anxiety or depression above moderate level
* Severe liver or kidney dysfunction, with transaminase or creatinine level exceeding twice of the normal value
* BMI ≥ 28 kg/m2
* Allergies to research drugs
* Other situations that doctor deems unsuitable to participate in the study
Minimum Eligible Age

40 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking Union Medical College Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rong Chen, Professor

Role: STUDY_DIRECTOR

Peking Union Medical College Hospital

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rong Chen, Professor

Role: CONTACT

010-13811030947

Lingjin Yang

Role: CONTACT

010-15650795133

References

Explore related publications, articles, or registry entries linked to this study.

Moline ML, Broch L, Zak R, Gross V. Sleep in women across the life cycle from adulthood through menopause. Sleep Med Rev. 2003 Apr;7(2):155-77. doi: 10.1053/smrv.2001.0228.

Reference Type BACKGROUND
PMID: 12628216 (View on PubMed)

Gold EB, Sternfeld B, Kelsey JL, Brown C, Mouton C, Reame N, Salamone L, Stellato R. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol. 2000 Sep 1;152(5):463-73. doi: 10.1093/aje/152.5.463.

Reference Type BACKGROUND
PMID: 10981461 (View on PubMed)

Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, Espie CA, Garcia-Borreguero D, Gjerstad M, Goncalves M, Hertenstein E, Jansson-Frojmark M, Jennum PJ, Leger D, Nissen C, Parrino L, Paunio T, Pevernagie D, Verbraecken J, Weess HG, Wichniak A, Zavalko I, Arnardottir ES, Deleanu OC, Strazisar B, Zoetmulder M, Spiegelhalder K. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017 Dec;26(6):675-700. doi: 10.1111/jsr.12594. Epub 2017 Sep 5.

Reference Type BACKGROUND
PMID: 28875581 (View on PubMed)

Kaplan KA, Hardas PP, Redline S, Zeitzer JM; Sleep Heart Health Study Research Group. Correlates of sleep quality in midlife and beyond: a machine learning analysis. Sleep Med. 2017 Jun;34:162-167. doi: 10.1016/j.sleep.2017.03.004. Epub 2017 Mar 27.

Reference Type BACKGROUND
PMID: 28522086 (View on PubMed)

Kenemans P, Speroff L; International Tibolone Consensus Group. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas. 2005 May 16;51(1):21-8. doi: 10.1016/j.maturitas.2005.02.011.

Reference Type BACKGROUND
PMID: 15883105 (View on PubMed)

Jiang XR, Ren L, Li CR. [Effect of Electroacupuncture on Hypothalamus-Pituitary-Ovary (HPO) Axis in Rats with Peri-menopausal Depression]. Zhen Ci Yan Jiu. 2017 Feb 25;42(1):45-9. Chinese.

Reference Type BACKGROUND
PMID: 29071997 (View on PubMed)

Chen R, Tang R, Zhang S, Wang Y, Wang R, Ouyang Y, Xie X, Liu H, Lv S, Shi H, Zhang Y, Xie M, Luo Y, Yu Q. Xiangshao granules can relieve emotional symptoms in menopausal women: a randomized controlled trial. Climacteric. 2021 Jun;24(3):246-252. doi: 10.1080/13697137.2020.1820476. Epub 2020 Oct 5.

Reference Type BACKGROUND
PMID: 33016149 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Informed Consent Form

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://rs.yiigle.com/cmaid/1038778

Guideline for the evaluation and treatment of insomnia in Chinese adults(2017)

https://rs.yiigle.com/cmaid/1445008

The 2023 Chinese menopause symptom management and menopausal hormone therapy guidelines

http://www.chinadoi.cn/portal/mr.action?doi=10.3969/j.issn.1009-0959.2014.12.017

Curative Effect Analysis on Xiang Shao Particle in the Treatment of Women Perimenopausal Syndrome

http://www.chinadoi.cn/portal/mr.action?doi=10.3321/j.issn:1003-3734.2002.05.014

Efficacy and safety of Jingqianping granule in treatment of 403 cases of the liver-qi invasion of premenstrual syndrome with multicentre, random,double-blind and double simulation and control method

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

menopausal sleep disorders

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.